CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

CAMP4 will brief analysts on CMP-002’s planned Phase 1/2 trial and SYNGAP1-related disorder via a webcasted Analyst Day.

Rhea-AI Summary

CAMP4 Therapeutics (CAMP) will host a virtual Analyst Day on September 28, 2026, from 12:00–1:30 PM ET to discuss CMP-002 for SYNGAP1-related disorder.

The event will feature CAMP4 leadership, a leading KOL, and patient advocates, covering unmet clinical need, the Phase 1/2 first-in-human trial design for CMP-002 expected to initiate in Q4 2026, and an update on the early discovery pipeline. The live webcast and 30-day replay will be available via the company’s investor relations website.

Key Figures

Analyst Day date: September 28, 2026 Analyst Day time: 12:00–1:30 PM ET Trial phase: Phase 1/2 +1 more

Analyst Day date

September 28, 2026

Virtual presentation on CMP-002 and SYNGAP1-related disorder

Analyst Day time

12:00–1:30 PM ET

Virtual presentation and Q&A

Trial phase

Phase 1/2

First-in-human CMP-002 clinical trial

Trial initiation timing

Q4 2026

Expected initiation of the CMP-002 trial

Key Terms

first-in-human, phase 1/2 clinical trial, disease-modifying therapy, kol

4 terms

first-in-human medical

"first-in-human Phase 1/2 clinical trial of CMP-002"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

phase 1/2 clinical trial medical

"overview of the clinical trial design for the Company’s first-in-human Phase 1/2 clinical trial"

A phase 1/2 clinical trial is an early human study that combines first-in-people safety and dosing checks (phase 1) with an initial look at whether the treatment appears to work (phase 2). Think of it as a short test drive where researchers both confirm the product won’t cause serious harm and gather early signs it could be effective; for investors, successful results reduce risk and can unlock value-creating milestones like larger trials or regulatory discussions.

disease-modifying therapy medical

"a potential first-in-class disease-modifying therapy for patients"

A disease-modifying therapy is a treatment that changes the underlying course of a progressive illness rather than only relieving symptoms—think of fixing a leaky pipe instead of just mopping the floor. For investors, these therapies can unlock bigger, longer-lasting clinical benefits and larger market potential if proven, but they also carry higher development, regulatory and adoption risk because proving a true change in disease over time is more difficult.

kol medical

"participation from patient advocates and a leading KOL"

A KOL, or key opinion leader, is a trusted expert—often a leading physician, researcher, or specialist—whose views influence peers, clinical practice, and industry adoption of medical products or treatments. For investors, KOL endorsements or criticisms can sway adoption rates, regulatory perceptions, and market confidence much like a respected critic can affect demand for a new product, so monitoring KOL sentiment helps gauge commercial and clinical prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadership team and participation from patient advocates and a leading KOL. To register, click here.

Live webcasts can be accessed on the investor relations page of CAMP4’s website at https://investors.camp4tx.com/. A replay of the webcast will be archived on the CAMP4 website for 30 days following the presentation.

The program will address the unmet clinical need in SYNGAP1-related disorder, and provide an overview of the clinical trial design for the Company’s first-in-human Phase 1/2 clinical trial of CMP-002, a potential first-in-class disease-modifying therapy for patients with SYNAGP1-related disorder, expected to initiate in Q4 2026. The Company will also provide an update on its early discovery pipeline.

Stéphane Auvin, MD, Ph.D., (Robert Debré University Hospital, Université Paris Cité) will join to discuss the unmet need and current treatment landscape for this condition.

A live question and answer session will follow the formal presentations.

About Stéphane Auvin, MD, PhD
Stéphane Auvin, MD, Ph.D., is a child neurologist and epileptologist, and a full professor at Robert Debré University Hospital & Paris-Diderot University, in Paris, France. Dr. Auvin is conducting the Epilepsy program at the center for rare epilepsies at Robert Debré University Hospital, APHP, Paris, and experimental research works in the INSERM U1141, Paris. His clinical and research activities are focused on pediatric epilepsy and its treatments. Dr. Auvin’s research team is working on inflammation-epilepsy, the ketogenic diet, and antiepileptic drugs in the developing brain. The Epilepsy program at Robert Debré Children Hospital, Paris, is involved in antiepileptic drugs development and clinical trials (PK, Phase II, Phase III and Phase IV). He is the author of more than 150 peer-reviewed papers or book chapters, and serves the ILAE (International League Against Epilepsy) as the chair of the Pediatric Commission (2017-2021), and as Associate Editor for Epilepsia. Dr. Auvin is also the president of the French Pediatric Neurology Society (2019-2022).

About SYNGAP1-Related Disorder
SYNGAP1-related disorder (also referred to as SYNGAP1) is a rare, haploinsufficient CNS disorder caused by mutations in the SYNGAP1 gene, resulting in approximately 50% of normal SYNGAP protein levels. The condition affects over 10,000 individuals in the United States and is characterized by intellectual disability in 100% of patients, epilepsy in approximately 85%, severe behavioral problems in approximately 70%, sleep problems in approximately 60%, and limited communication, with approximately 30% of patients being non-verbal. There are currently no approved disease-modifying therapies for patients living with SYNGAP1.

About CMP-002
CMP-002 is CAMP4's lead investigational antisense oligonucleotide (ASO) therapeutic candidate designed to bind to a SYNGAP1-specific regRNA to increase SYNGAP1 gene expression and restore SYNGAP protein toward near wild-type levels. Administered intrathecally, CMP-002 has demonstrated dose-dependent increases in SYNGAP protein expression in patient-derived neurons, reversal of disease-relevant behavioral phenotypes in a humanized haploinsufficient mouse model, statistically significant improvement of seizure phenotypes and parameters in a chemically induced seizure mouse model, and broad brain distribution with significant SYNGAP protein upregulation in non-human primates.

About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform^® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning the anticipated timeline for initiation of the Company’s planned Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder; the therapeutic potential of CMP-002 and the Company’s other product candidates; the potential of the Company’s RAP Platform technology and early discovery pipeline; and the Company’s strategy, goals, business plans and focus. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since inception and anticipated incurrence of substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve its goals; the uncertainty of clinical development and risks related to additional costs or delays in the development and commercialization of the Company’s product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates; the Company’s ability to obtain and maintain sufficient intellectual property protection for its product candidates; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com

Media:
Sofia Bermudez
LifeSci Communications
sbermudez@lifescicomms.com

FAQ

How can investors and analysts access CAMP4’s virtual Analyst Day?

Registration is available online via a provided link, and the live webcast can be accessed on the investor relations page of CAMP4’s website at https://investors.camp4tx.com/. A replay of the webcast will be archived on the CAMP4 website for 30 days following the presentation.

What topics will be covered during CAMP4’s Analyst Day on CMP-002?

The program will address the unmet clinical need in SYNGAP1-related disorder, provide an overview of the clinical trial design for the planned first-in-human Phase 1/2 trial of CMP-002 expected to initiate in Q4 2026, offer an update on CAMP4’s early discovery pipeline, and include a discussion of the unmet need and current treatment landscape by Stéphane Auvin, MD, Ph.D.